(VIANEWS) – SPBK1 NORD-NORGE (NONG.OL), HOLLAND COLOURS (HOLCO.AS), SANOFI (SAN.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPBK1 NORD-NORGE (NONG.OL)
16.3% sales growth and 16.76% return on equity
SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market and Corporate Market segments. The company offers mortgage, car, boat, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers accounting services, real estate brokerage, and leasing/sale-leaseback financing, internet banking, and mobile services. SpareBank 1 Nord-Norge was founded in 1836 and is headquartered in Tromsø, Norway.
Earnings Per Share
As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr12.37.
PE Ratio
SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 8.67. Meaning, the purchaser of the share is investing kr8.67 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.76%.
Sales Growth
SPBK1 NORD-NORGE’s sales growth is 20% for the current quarter and 16.3% for the next.
Yearly Top and Bottom Value
SPBK1 NORD-NORGE’s stock is valued at kr107.22 at 12:20 EST, below its 52-week high of kr110.70 and way higher than its 52-week low of kr91.90.
More news about SPBK1 NORD-NORGE.
2. HOLLAND COLOURS (HOLCO.AS)
13.8% sales growth and 8.62% return on equity
Holland Colours N.V., together with its subsidiaries, manufactures, distributes, and sells color concentrates in Europe, North America, Asia, and internationally. The company offers colorants for the building and construction industry, including profiles, pipes, tubing and fittings, siding and cladding, decking, fencing, window blinds, and insulation, as well as solutions for a range of polymers. It offers colorants for packaging applications comprising water, carbonated soft drinks, fruit juices, dairy, beer, wine, detergents, pharmaceutical, and personal care products. In addition, the company offers v, sealants, or adhesives; and colorants for other applications, such as shopping bags, polybags, mulch films, OPP tapes, PU flexible foams, synthetic leather, fiber glass and buttons, paving blocks, artificial stones, cast PMMA, PP non-woven and spunbond, coatings, flexible PVCs, prosthetics, glass fiber reinforced nylon, and silicone rubber and elastomers. It sells its products through a network of suppliers, agents, and distributors. The company was founded in 1979 and is headquartered in Apeldoorn, the Netherlands. Holland Colours N.V. operates as a subsidiary of Holland Pigments BV.
Earnings Per Share
As for profitability, HOLLAND COLOURS has a trailing twelve months EPS of €6.02.
PE Ratio
HOLLAND COLOURS has a trailing twelve months price to earnings ratio of 15.61. Meaning, the purchaser of the share is investing €15.61 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.62%.
More news about HOLLAND COLOURS.
3. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Moving Average
SANOFI’s value is below its 50-day moving average of €97.73 and under its 200-day moving average of €91.63.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
More news about SANOFI.
4. CREDIT AGRICOLE (ACA.PA)
6.1% sales growth and 7.17% return on equity
Crédit Agricole S.A. provides retail, corporate, insurance, and investment banking products and services in France and internationally. It operates through French Retail Banking – Regional Banks; French Retail Banking – LCL; International Retail Banking; Asset Gathering; Large Customers; and Specialised Financial Services segments. The company offers banking products and services, finance, savings, wealth management, payment, and cash flow management services; consumer finance products; savings/retirement, death and disability/creditor/group, and property and casualty insurance products; investment solutions; and banking and specialized financial services. It also provides investment banking, structured finance, international trade finance, commercial banking, capital market, and syndication services; financing solutions for property and equipment investment and renewal requirements; trade receivable financing and management solutions for corporates; asset servicing solutions for investment products, as well as various asset classes, such as execution, clearing, forex, security lending and borrowing, custody, depositary bank, fund administration, middle-office outsourcing solutions, and fund distribution support and issuer services; and online banking services. The company serves retail customers, corporates, banks and financial institutions, government agencies, and local authorities. Crédit Agricole S.A. was founded in 1894 and is headquartered in Montrouge, France. Crédit Agricole S.A. operates as a subsidiary of SAS Rue La Boetie.
Earnings Per Share
As for profitability, CREDIT AGRICOLE has a trailing twelve months EPS of €1.94.
PE Ratio
CREDIT AGRICOLE has a trailing twelve months price to earnings ratio of 7.12. Meaning, the purchaser of the share is investing €7.12 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.17%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 29, 2024, the estimated forward annual dividend rate is 1.05 and the estimated forward annual dividend yield is 7.38%.
Sales Growth
CREDIT AGRICOLE’s sales growth is 3.3% for the present quarter and 6.1% for the next.
Moving Average
CREDIT AGRICOLE’s value is higher than its 50-day moving average of €13.72 and higher than its 200-day moving average of €13.60.
More news about CREDIT AGRICOLE.
